- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01386684
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study
November 21, 2018 updated by: AbbVie (prior sponsor, Abbott)
Canadian Real-Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer (CRONOS)
The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design.
Patients with Prostate Cancer who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6, 12, 18, 24, 30 and 36 months after baseline.
Treatment of the patients and follow up will be according to the physician's judgment, regional regulations and the product monograph.
Study Type
Observational
Enrollment (Actual)
552
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients will be enrolled from the offices of university or community urologists/oncologists across Canada treating patients with PCa.
Description
Inclusion Criteria:
- Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
- Diagnosed with Prostate Cancer
- Prescribed Lupron as part of his treatment by his treating physician
Exclusion Criteria:
- Currently participating in another prospective study including controlled clinical trials and observational studies.
- Patient cannot or will not sign informed consent
- Survival expectancy less than 2-3 years as per the treating physician's judgment
- Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer
- History of alcohol or drug abuse
- No longer than 6 months of therapy if currently on luteinizing hormone-releasing hormone (LHRH) treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Patients with Prostate Cancer
Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free Survival (PFS) Defined as the Time From Patient Recruitment to Biochemical Progression Based on Doubling of Prostate Specific Antigen (PSA) Velocity or PSA > 5.0
Time Frame: 36 months
|
PFS defined as the time from patient recruitment to biochemical progression based on doubling of prostate specific antigen (PSA) velocity or PSA > 5.0, objective tumor progression (RECIST criteria), or death.
The distribution of PFS was estimated using Kaplan-Meier methodology.
The point estimate and standard error (SE) of the distribution are provided.
|
36 months
|
|
Progression-free Survival (PFS) Defined as the Time From Patient Recruitment to a Change to an Absolute Value of PSA > 2 ng/mL on at Least 2 Consecutive Tests
Time Frame: 36 months
|
A second definition of PFS was used due to changes in the definition of biochemical progression: the time from patient recruitment to a change to an absolute value of PSA > 2 ng/mL on at least 2 consecutive tests, objective tumor progression (RECIST criteria), or death.
The distribution of PFS was estimated using Kaplan-Meier methodology.
The point estimate and standard error (SE) of the distribution are provided.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Castration Resistant Prostate Cancer (CRPC): Number of Participants
Time Frame: 36 months
|
CRPC defined as PSA > 2 ng/mL on at least 2 consecutive tests.
|
36 months
|
|
Castration Resistant Prostate Cancer (CRPC): Time to Event
Time Frame: 36 months
|
CRPC defined as PSA > 2 ng/mL on at least 2 consecutive tests.
The distribution of time to CRPC was estimated using Kaplan-Meier methodology.
The point estimate and standard error of the distribution are provided.
|
36 months
|
|
Total Serum Testosterone: Percentage of Participants With ≤ 0.7 Nmol/L, > 0.7 to ≤ 1.7 Nmol/L, and > 1.7 Nmol/L at Each Visit
Time Frame: Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
Total serum testosterone was assessed at each study visit.
The percentage of participants with total serum testosterone ≤ 0.7 nmol/L, > 0.7 to ≤ 1.7 nmol/L, and > 1.7 nmol/L are provided at each time point.
|
Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
|
Total Serum Testosterone Levels at Each Visit
Time Frame: Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
Total serum testosterone was assessed at each study visit.
|
Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
|
Total Serum Testosterone: Time to Increase Over Castrate Levels
Time Frame: 36 months
|
Total serum testosterone was assessed at each study visit.
The time to increased total serum testosterone over the castrate levels (>1.7 nmol/L) are provided.
The distribution of time to increase in total serum testosterone levels was estimated using Kaplan-Meier methodology.
The point estimate and standard error (SE) of the distribution are provided.
|
36 months
|
|
Prostatic Specific Antigen (PSA): Percentage of Participants With Serum PSA < 1 ng/mL, 1 to < 5 ng/mL, 5 to < 10 ng/mL, and ≥10 ng/mL at Each Visit
Time Frame: Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
Serum PSA was assessed at each study visit.
The percentage of participants with serum PSA < 1 ng/mL, 1 to < 5 ng/mL, 5 to < 10 ng/mL, and ≥10 ng/mL are provided at each time point.
|
Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
|
Prostatic Specific Antigen (PSA) Levels at Each Visit
Time Frame: Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
Serum PSA was assessed at each study visit.
|
Months 0 (Baseline), 3, 6, 12, 18, 24, 30, and 36
|
|
Functional Assessment of Cancer Therapy Questionnaire - General (FACT-G) Total Score: Change From Baseline to Each Visit
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The FACT-G questionnaire is used with patients of any tumor type to assess patient quality of life (QoL).
FACT-G is a self-administered, 28-item questionnaire assessing physical, functional, social and emotional well-being, as well as patient satisfaction with treatment.
All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much).
The FACT-G total score is computed as the sum of the four subscale scores and has a possible range of 0-108.
Higher scores indicate better QoL.
Change in FACT-G was analyzed using repeated measures mixed effects general linear model (GLM).
A positive change from baseline indicates improved QoL.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Functional Assessment of Cancer Therapy Questionnaire - Prostate Cancer (FACT-P) Total Score: Change From Baseline to Each Visit
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The FACT-P questionnaire is used with patients with prostate cancer to assess patient quality of life (QoL).
FACT-P is a self-administered, 28-item questionnaire assessing physical, functional, social and emotional well-being, as well as patient satisfaction with treatment.
All questions in the FACT-P use a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much).
The FACT-P total score is computed as the sum of the four subscale scores and has a possible range of 0-108.
Higher scores indicate better QoL.
Change in FACT-P was analyzed using repeated measures mixed effects general linear model (GLM).
A negative change from baseline indicates decreased QoL.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
International Index of Erectile Function (IIEF-5) Total Score: Change From Baseline to Each Visit
Time Frame: Month 0 (Baseline) and Months 6, 12, 18, 24, 30, and 36
|
IIEF-5 is a 5-item, self-administered questionnaire assessing the presence and severity of erectile dysfunction.
A score of 1 (very low) to 5 (very high) is awarded to each of the 5 questions.
The IIEF-5 total score is a sum of the responses to the 5 items.
Total scores range from 5 to 25, with higher scores indicating less dysfunction.
Change in IIEF-5 was analyzed using repeated measures mixed effects general linear model (GLM).
A negative change from baseline indicates an increase in dysfunction.
|
Month 0 (Baseline) and Months 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants With Medical Insurance for Prescription Medications
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Physician for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Visits With a Physician for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Healthcare Professional for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Visits With a Healthcare Professional for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Hospital Emergency Room for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Visits to A Hospital Emergency Room for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Used an Ambulance Service for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Times That an Ambulance Service Was Used for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited Complementary/Alternate Therapy for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Visits For Complementary/Alternate Therapy for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Used Any Other Medical Service for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Visits For Any Other Medical Service for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Were Admitted to the Hospital for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Number of Admissions to the Hospital for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Over-the-counter Medications for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Payments to Health Care Professionals for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Medical Procedures for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Payments for Medical Procedures or Laboratory Tests for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Medical Devices for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Health Care or Extra Help At Home for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Transportation Costs for Prostate Cancer
Time Frame: Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
The Health Care Utilization and Health Economics Questionnaire is a descriptive, self-administered series of questions aimed at measuring the patient's health care utilization and economic impact of the disease.
The questionnaire was used to assess since the last visit the frequency of physician visits; utilization of other health care professionals; visits to clinics, emergency rooms, and hospitalizations related to prostate cancer; use of prescription and non-prescription medications for the management of prostate cancer were determined; and out of pocket expenses for medications and health care.
|
Month 0 (Baseline) and Months 3, 6, 12, 18, 24, 30, and 36
|
|
Treatment Compliance
Time Frame: Months 3, 6, 12, 18, 24, 30, and 36
|
Treatment compliance by participants was assessed as the number of missed injections since the last visit.
|
Months 3, 6, 12, 18, 24, 30, and 36
|
|
Percentage of Participants With Changes in Current Prostate Cancer Treatment Since Last Visit.
Time Frame: Months 3, 6, 12, 18, 24, 30, and 36
|
Participants were asked "Have there been any changes in the current prostate cancer treatment (not including Lupron) since last visit?";
if Yes, was the change "Initiation of new mediation/Change in Dose/Frequency" or "Discontinuation of medication".
The percentage of subjects at each visit with a change in current prostate cancer treatment (Initiation or Change in Dose/Frequency or Discontinuation of Medication) is presented.
|
Months 3, 6, 12, 18, 24, 30, and 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 28, 2011
Primary Completion (ACTUAL)
September 8, 2016
Study Completion (ACTUAL)
September 8, 2016
Study Registration Dates
First Submitted
June 30, 2011
First Submitted That Met QC Criteria
June 30, 2011
First Posted (ESTIMATE)
July 1, 2011
Study Record Updates
Last Update Posted (ACTUAL)
December 13, 2018
Last Update Submitted That Met QC Criteria
November 21, 2018
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P12-811
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.Active, not recruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer... and other conditionsUnited States